**Article type:** Original article 1 2 Title: "Genomic and phenotypic characterization of Investigator Global Assessment (IGA) scale 3 based endotypes in atopic dermatitis" 4 Sandra P Smieszek<sup>1</sup>, Bart Przychodzen<sup>1</sup>, Sarah E Welsh<sup>1</sup>, Jennifer Brzezynski<sup>1</sup>, Alyssa Kaden<sup>1</sup>, 5 Michael Mohrman<sup>1</sup>, Jim Wang<sup>1</sup>, Changfu Xiao, Christos Polymeropoulos <sup>1</sup>, Gunther Birznieks<sup>1</sup>, 6 7 Mihael H Polymeropoulos<sup>1</sup> <sup>1</sup> Vanda Pharmaceuticals, 2200 Pennsylvania NW, Suite 300-E, Washington, DC 20037 8 9 Twitter handle: @vandapharma 10 **Corresponding author:** 11 12 Sandra P. Smieszek 2200 Pennsylvania NW, Suite 300-E 13 Washington, DC 20037 14 Email: sandra.smieszek@vandapharma.com 15 16 17 **Funding sources**: Vanda Pharmaceuticals 18 **Conflicts of Interest**: SPS is an employee of Vanda and a stockholder. BPP is an employee of 19 Vanda and a stockholder. SEW is an employee of Vanda and a stockholder. JB is an employee 20 of Vanda and a stockholder. AK is an employee of Vanda and a stockholder. MM is an employee 21 of Vanda and a stockholder. CX is an employee of Vanda and a stockholder. CP is an employee 22 of Vanda and a stockholder. GB is an employee of Vanda and a stockholder. MHP is Chief 23 24 Executive Officer of Vanda. 25 26 IRB approval status: Reviewed and approved by Advarra IRB; Pro00025510 27 Clinicaltrials.gov listing: NCT03568331 28 29 30 **Keywords:** Atopic dermatitis; itch; endotypes; whole genome sequencing; cytokines 31 32 33

**ABTRACT limited to 200 words** 

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

2

Background: Atopic dermatitis (AD) is a heritable and heterogeneous inflammatory chronic skin disorder. Utilizing decision tree/ supervised learning of extensive clinical, molecular and genetic data, we aimed to define distinct AD endotypes. Methods: Deep phenotyping and whole-genome sequencing was performed on samples obtained from participants of EPIONE, a phase III study in AD patients with severe pruritus: mild (23%) to moderate (64%) and severe (13%) as determined by validated Investigator Global Assessment scale for Atopic dermatitis (vIGA-AD<sup>TM</sup>). Three categories of analysis were performed: clinical associations, lab value associations (EOS, IgE, cytokines) and genetic analysis of whole-genome sequencing data Results: Based on a decision tree, we found that mild AD presents with fewer lesions with mild erythema and minimal induration/papulation or oozing/crusting. In contrast, severe AD presents with a larger number of erythematous lesions associated with significant induration/papulation or oozing/crusting. We observe a significant differences between severity and eosinophil counts (p < 0.001), IgE (p < 0.001) and Filaggrin (FLG) LOF frequency (OR 2.3 CI 1.6-3.2 p < 0.0001) as well as interleukin pathway genes, specifically IL5RA variants differentiating the groups. Conclusion: Our results suggest significant differences between severity groups across a number of features appear to constitute distinct endotypes with likely distinct causative factors. Differing underlying pathophysiology's indicate endotype knowledge is critical to help guide therapeutic approaches to AD.

#### Capsule summary [cannot exceed 50 words]

- AD is a heritable and heterogeneous skin disorder that makes the 'one size fits all' therapeutic approach suboptimal for patients with AD.
- We attempted to define AD endotypes based on clinical, molecular, and genetic characteristics. Clinical, CBC, and genetic associations all tend to suggest existence of separate endotypes.

#### Introduction

Atopic dermatitis (AD) is a complex and heterogeneous, highly heritable, chronic, inflammatory skin disorder. AD affects 7.3% of US adults<sup>1</sup>,<sup>2</sup>. The genetic background of AD is complex and likely composed of a mixture of rare and common variants. The heritability of AD is estimated to be around 75%<sup>2</sup>. Studies have shown that there are genetic factors specific to AD beyond those for general atopy<sup>3,4</sup>. AD is manifested by a wide range of symptoms and significantly impacts quality of life. Flares are usually characterized by extreme pruritus of red, rough, flaky and often fissured regions of the skin, that over time thicken<sup>2</sup>. Chronic pruritus, lasting more than 6 weeks, is a key feature associated with AD. The extent of skin lesions and other physical symptoms vary within this patient population and can be diagnosed as mild, moderate, or severe as defined by the Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD<sup>TM</sup>). The etiology is likely resultant from an interaction between the genetically determined skin barrier, immune system dysregulation, and the environmental triggers<sup>2</sup>.

One of the main functions of the skin is to act as a barrier between the individual and the environment, preventing water loss and at the same time preventing pathogen and allergen entry<sup>5</sup>. Skin barrier dysfunction is a key clinical feature of AD, as this facilitates penetration of allergens, immunological dysfunction, and consequently an increased risk of developing eczema<sup>5,6</sup>. The skin barrier dysfunction has been associated with the etiology of the itch-scratch cycle<sup>7</sup>. In addition, genes encoding skin barrier proteins have been shown to play a role in the heritability of  $AD^{8,9}$ . Loss-of-function (LOF) variants resulting in aberrant *FLG* production, constitute the best-known AD gene-association and have been shown to predispose individuals to  $AD^{10,11}$ . Individuals harboring *FLG* LOF variants manifest clinical features such as dry and fissured skin. LOF variants in *FLG* are associated with lower levels of natural moisturizing factors (NMF) in  $AD^{12}$ . Additional genes involved in skin barrier function, including epidermal differentiation complex (EDC) proteins, are thought to have a potential role in AD. The EDC encodes proteins critical to the proper development of keratinocytes and normal formation of the skin barrier<sup>13</sup>. Downregulation of EDC genes has also been implicated in  $AD^{14,15,16,17}$ .

Disrupted skin barrier promotes penetration of allergens, immunological dysfunction, and consequently an increased risk of developing eczema<sup>18</sup>. Critical features of the TH2 immune response include local production of TH2 cytokines activation of eosinophils (EOS) and mast cells, as well as production of IgE<sup>19</sup>. Ultimately T-cell subsets, including Th2/Th22 cells, are upregulated in AD skin<sup>20</sup>. Interestingly both lesional and nonlesional AD showed a highly polyclonal T cell receptor pattern, insinuating the lasting presence of potentially pathogenic memory T cells beyond clinically inflamed lesions<sup>20</sup>. Ultimately dysregulation leads to increased production of neuropeptides such as substance P (SP) released from primary sensory nerves in the skin<sup>21</sup>. SP binds the neurokinin-1 receptor (NK1R) and MRGPRS<sup>22</sup>. Elevated SP levels have been observed in the blood and lesional skin of AD patients, and have been correlated with itch intensity, as shown in challenge studies and further reiterated in transcriptome analysis <sup>23</sup>, <sup>7</sup>. Elevated SP levels further elicit vasodilation of short duration leading to mast cell degranulation, nerve growth factor expression in keratinocytes, and neurogenic inflammation associated with erythema and pruritus<sup>21</sup>. Proof of concept studies have shown increases in itch resulting from injected SP and expression of NK1R in keratinocytes, as well as reduction in itch resulting from inhibition of NK1R. Pruritus, perpetuates scratching that further damages the skin barrier.

Our work aimed to evaluate the effect of clinical manifestations, molecular levels and genetic associations and cytokine levels to further understand the architecture and variability of AD as

assessed in subjects during baseline visit. We aim to discern whether degree of severity recapitulates individual endotypes in AD.

#### **Results**

106

107

108

109

110

111112

113

114

115116

117

118119

120

121

142

EPIONE, a multi-center, placebo-controlled, double-blind study, enrolled and randomly assigned (1:1) 341 patients aged 18 to 70 with AD Welsh et al., 2020 (manuscript under review) describes the efficacy and safety results from EPIONE. At baseline, participants presented with a range of disease severities from mild (23%) to moderate (64%), and severe (13%). Severity was defined by Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD<sup>TM</sup>). For analysis, mild AD as IGA scores of 1 (1) or 2 (77) at baseline, while more severe AD was defined as IGA scores of 3 (218) or 4 (33). In addition to deep phenotyping we obtained AD samples for whole genome sequencing (n=765 entire study population, n=332 randomized patients). **Table 1** shows demographic and clinical characteristics of the studied cohort at baseline. **Figure 1** depicts the baseline clinical and lab measurements across IGA groups. We examine each sub-component in depth in the sections that follow.

#### **Clinical Association**

- We collected extensive clinical information using the SCORAD index including total area
- involved, intensity, and subjective measurements<sup>24</sup>, <sup>25</sup>. Canonically, we observe that mild AD
- presents with fewer lesions, mild erythema, and minimal induration/papulation or
- oozing/crusting. In contrast, severe AD presents with a larger number of erythematous lesions
- associated with significant induration/papulation, oozing/crusting. Importantly, we observed that
- the interaction between three most informative variables (Edema/Papules, Erythema and Total
- Area Affected) can classify patients by disease severity. The most severe patients present almost
- exclusively with highest SCORAD Edema/Papules score (3 on a 0-3 scale) or SCORAD
- Erythema (3 on a 0-3 scale). Utilizing only those two variables we can accurately identify 35.8%
- of IGA3/4 with only 2.5% of IGA1/2 falling into that category (**Figure 2A-B**). Remaining 64.2%
- of IGA3/4 patients are more difficult to distinguish from IGA1/2. There is a clear separation of
- the remaining IGA3/4 patients by the SCORAD Total Affected Area (**Figure 2C**).
- We performed a series of classification and regression analyses to understand the underlying
- nature of the severity subgroups utilizing multiple clinical variables at once. We focus our
- analysis using classification trees. Based on a series of five clinical features from the SCORAD
- scale, we were able to accurately differentiate between IGA 1/2 versus IGA 3/4. We obtained a
- robust classification using SCORAD Total Affected Area (%), Edema/Papules, Erythema,
- Lichenification, and Excoriation. Five-fold cross-validation classification (J48) yields weighted
- 140 83.8% precision and 80.1% recall and a large AUC 0.830. **Supplementary Figure 1** displays the
- actual tree (J48) revealing the cutoffs and splits.

#### **Eosinophils and IgE**

- Motivated by the hypothesis that atopy is key in the expression of AD, we evaluated the role of
- counts of eosinophils and levels of IgE and their association with the clinical expression of AD.
- We evaluated lab values (EOS, IgE, systemic cytokines) that may differentiate milder from more
- severe AD. We detect a significant association between IGA and EOS levels. We have shown
- that more severe AD (IGA3/4) is associated with significantly higher counts of eosinophils as

- 148 compared to milder AD (IGA1/2) (**Figure 1**), an effect that is significant (Mann-Whitney p-
- value < 0.01). The effect is persistent in an extended screening cohort of 765 samples. Moreover
- there is a significant difference between IGA 3 and 4 in the EOS levels (p-value < 0.0008) and
- 151 1/2 vs. 4 (p < 0.0001). This suggests that systemic eosinophil levels are increasingly correlated
- across the IGA severity scale. All but 3 cases of the 32 cases above 0.5 are moderate to severe
- AD subjects (29/282 of IGA3/4 and only 3/79 IGA1/2). Additionally, we report a significant
- difference in distribution of patients with elevated serum IgE (**Figure 1D**, level > 100 IU/mL p-
- 155 value < 0.001).

156

175

#### Genetic landscape of AD endotypes

- We performed whole genome sequencing of the entire study population (n=765). We
- investigated the incidence of all *FLG* LOF variants in the genomes of the EPIONE study
- patients, and compared them with the whole genome sequences of a control population (n=316).
- of healthy volunteers as well as individuals from gnomAD databaseMore severe AD is
- associated with a higher prevalence of *FLG* LOF variants (p value < 0.0001, OR 2.3 CI 1.6-3.2).
- This is significant enrichment as compared to milder (p-value = 0.99, OR = 0.89 CI = 0.3-2.0).
- Milder AD has incidence of LOF *FLG* variants comparable to normal population as defined by
- gnomAD and an internal set of controls (IGA1/2: 6.4%, Vanda Controls: 6.2%, GnomAD: 8.4%)
- whereas the moderate to severe subgroup has an elevated frequency of LOF *FLG* variants
- 166 (IGA3/4: 17.7%). This is contrary to the general observation that AD cases have higher
- prevalence of *FLG* mutations than the control population, as this effect seems to be specific to
- 168 IGA3/4 subjects. The variants detected are depicted on **Figure 3** which displays the location of
- individual LOF variants in both endotypes. We have now showed that the increased frequency
- can be ascribed to the severe AD subtypes. The results are consistent for EDC gene
- variantsFurthermore, we detect higher frequency if individuals with two or more FLG mutations
- in the severe group as well as incidence of cases with CNV within the *FLG* gene present in the
- 173 IGA3/4. The allelic frequency of the two prevalent *FLG* LOF variants, p.R501\* and p.S761fs as
- well as the OR is displayed on panel B of **Figure 3**.

#### *IL5RA* gene rare variants differentiate between IGA subgroups

- We have performed *in silico* interleukin (IL) screen using gene-centric collapsing analysis on a
- pathway of IL genes as defined by GO terms, comprised of 96 genes. In a rare variant analysis
- we obtain a significant result after conservative multiple hypothesis testing in IL5RA as
- differentiating between the two severity groups). Direction of effect is consistent with a higher
- EOS levels observed in IGA3/4. Binding of IL-5 to the α-subunit of the IL5Ra promotes the
- heterodimerization of iL-5R $\alpha$  and  $\beta$ c subunits. As a result, many signal transduction pathways
- are activated, including JAK/STAT modules, MAPK, Pi3K, and NF-κB. The stimulation of these
- kinases and TFs drives the expression of key genes responsible for differentiation, survival,
- degranulation, adhesion, and recruitment of eosinophils. Furthermore through whole genome
- sequence analysis we have also discovered that polymorphisms in the IL5Ra gene are associated
- with higher count of eosinophils in this population of AD patients. The IL5Ra rare variant
- rs200005614 associates with significantly higher level of EOS consistent with the effect
- observed. Previously other variants were found to be associated with EOS such as *IL5RA*
- c.-5091G>A which was shown to be associated with eosinophil count. IL5RA plays an
- important role in coordinating the release of eosinophil and IgE production against antigens

- leading to the development of atopy. The association of the IL5RA variants with the blood
- eosinophil counts and the severe IGA) indicates that the IL5RA gene has a role for controlling
- 193 crucial role in eosinophil responses.

#### Cytokines

194

- We measured a panel of systemic cytokines collected at baseline. We evaluated which cytokines
- at baseline are above the normal ranges (as defined by clinical standards<sup>26</sup> and show the results
- on a heatmap of ratios to reference range. This is displayed on **Figure 4** (log2 ratio of cytokine to
- a maximum value reported in reference range, red being above threshold levels levels). The
- observed trends are suggestive of elevated levels of Th2 (IL-4, IL-5, and IL-13). Increased IL-5,
- as well as IL-4 and IL-23 form a distinct, predominant group of patients (**Figure 4**).
- Interestingly, there is a subgroup of patients that also have elevated IL-6, IL-8, and IL-13 (blue
- ribbon highlight on **Figure 4**). IL-5 is produced by type 2 T helper cells and mast cells. It
- stimulates B cell growth and increases immunoglobulin secretion, and primarily is the key
- mediator of eosinophil activation. Its high expression has been previously associated with
- 205 chronic AD. It stimulates activated B cell and T cell proliferation, and differentiation of B cells
- into plasma cells. IL-4 has been implicated in tissue inflammation and epidermal barrier
- dysfunction<sup>27</sup>. These patients have decreased IFN-gamma and IL-12 levels across all patients,
- 208 not limited to patients with elevated Th2. Whereas the main signature pattern (elevated IL-4, IL-
- 5, and IL-23) is still as abundant in IGAs 1/2 and even 3s, subjects defined as 4 lack a subgroup
- of patients with high level of IL-6, IL-8, and IL-13. **Figure 5**, displays the cytokine levels in IGA
- subgroups. There is a distinct group of patients across all IGA severities that has low systemic
- levels of all cytokines. In addition many more severe outliers have several magnitude higher
- levels across the entire cytokine panel as compared to milder cases.

#### Discussion

- Defining AD subtypes has been a debated subject in the field. Definitions analogous to asthma
- 216 have been used based on elevated IgE: with presence ("extrinsic") or absence ("intrinsic") of
- increased IgE<sup>28</sup>. According to epidemiological studies, mild AD is the most common type of AD,
- affecting approximately 60% of AD cases (Atopic Dermatitis in America Study). The factors
- 219 underlying severity are not well understood. We present here clinical and genetic evidence
- suggesting that AD may be composed of distinct endotypes. Clinical features suggest milder and
- severe AD appear to be distinct entities that can be differentiated by five clinical features from
- the SCORAD index. . More severe AD is associated with a higher prevalence of mutation burden
- in the FLG skin barrier structural protein. Consistent with previous investigations, including a
- study in Denmark on (n=470) patients with  $AD^{29}$ , as well as extensive studies of *FLG* gene<sup>5</sup>.
- We have reported that more severe AD is associated with significantly higher count of
- eosinophils as compared to milder AD. Eosinophils are mediators of the inflammatory response
- and are responsible for recruiting other immune cells in the lesions. As such, it is likely that
- severe pruritus associated with both mild and severe AD may have different mediators. Based on
- our findings we hypothesize that the contribution of SP in mild AD, in generating and
- 230 transmitting the pruritic signal, may be relatively more significant than that seen in severe AD.
- Through whole genome sequence analysis we have also discovered that polymorphisms in the
- IL5Ra gene are associated with higher count of eosinophils in this population of AD patients.
- The association between eosinophils and IL5RA has been previously reported in asthmatic

234 patients. Here we find the association by gene-centric testing between the two severity groups. 235 This is in agreement with a reported association of rs2522411 variant in the IL-5 gene which was significantly associated with extrinsic AD<sup>30</sup>. When evaluating IL genes we detect IL5RA rare 236 237 variants further differentiating between severities, with rare IL5RA variants accumulating in the more severe cases. 238 The described findings lend credence to the existence of endotypes within AD that are 239 240 manifested clinically and are becoming more understood in terms of underlying mechanisms. These findings may have implications for both diagnosis and treatment course of the disorder. As 241 242 seen in (Welsh et al. 2020, manuscript under review) a robust anti-pruritic effect was observed in only the IGA1/2 population while the difference from placebo was not significant in the more 243 244 severe IGA population. Endotype analyses define the underlying clinical and genetic factors of mild versus more severe AD, and would indicate that the immune response and skin barrier 245 246 dysfunction tends to be increased in more severe AD. This may mean treating such patients may 247 require more immunological therapies. In contrast, mild patients without such underlying factors may be better served with direct targeted therapies such as an anti-pruritic agent addressing the 248 249 severe itch they may still experience despite their lesions being almost clear or mild. Further 250 attempts to define AD endotypes should be made to define the optimal therapeutic approach,

moving towards precision medicine-based treatment of AD based on clinical, molecular, and

251

252

genetic characteristics.

#### Acknowledgements

253

We are grateful to all the study participants and all whom made the study possible

- 255 Figure legend
- Figure 1. Atopic dermatitis endotypes
- Figure 2. Differences between mild and moderate to severe subtypes in terms of clinical feature
- 258 space

263

264

- 259 **Figure 3**. FLG LOF variants across IGA endotypes
- **Figure 4**. Cytokine panel at baseline (ratio to reference range)
- Figure 5. Individual cytokine scatter plots

#### Table legend

**Table 1**. Baseline demographic and clinical characteristics

	Overall
	N=341
Age, mean (SD)	41.6 (15.3)
Male, n (%)	118 (34.6)
Ethnic origin, n (%)	
White	228 (66.9)
Black	83 (24.3)
Asian	19 (5.6)
Other	11 (3.2)
BMI $(kg/m^2)$	28.2 (5.2)
WI-NRS	8.2 (1.3)
BSA	14.21 (17.2)
SCORAD	50.5 (14.5)
EASI	10.54 (10.4)
vIGA-AD, n (%)	
Almost Clear (1)	2 (0.6)
Mild (2)	77 (22.6)
Moderate (3)	218 (63.9)
Severe (4)	44 (12.9)
Eosinophil Count (10 <sup>9</sup> /L)	0.25 (0.2)
FLG LOF	51 (15.4)


IgE, n (% of 
$$\gg$$
 100 kU/L) 167 (49.0)

#### References

- Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic Dermatitis in America
   Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic
   Dermatitis in the US Adult Population. *J Invest Dermatol*. 2019;139(3):583-590.
   doi:10.1016/j.jid.2018.08.028
- Stein SL, Cifu AS. Management of Atopic Dermatitis. *JAMA*. 2016;315(14):1510-1511.
   doi:10.1001/JAMA.2016.1459
- Dold S, Wjst M, von Mutius E, Reitmeir P, Stiepel E. Genetic risk for asthma, allergic rhinitis, and atopic dermatitis. *Arch Dis Child*. 1992;67(8):1018-1022.
   doi:10.1136/adc.67.8.1018
- Barnes KC. An update on the genetics of atopic dermatitis: scratching the surface in 2009.
   *J Allergy Clin Immunol*. 2010;125(1):16-29.e1-11; quiz 30-31.
   doi:10.1016/j.jaci.2009.11.008
- Chen H, Common JEA, Haines RL, et al. Wide spectrum of filaggrin-null mutations in atopic dermatitis highlights differences between Singaporean Chinese and European populations. *Br J Dermatol*. 2011;165(1):106-114. doi:10.1111/j.1365-2133.2011.10331.x
- 6. Gao P-S, Rafaels NM, Hand T, et al. Filaggrin mutations that confer risk of atopic dermatitis confer greater risk for eczema herpeticum. *J Allergy Clin Immunol*. 2009;124(3):507-513, 513.e1-7. doi:10.1016/j.jaci.2009.07.034
- Nattkemper LA, Tey HL, Valdes-Rodriguez R, et al. The Genetics of Chronic Itch: Gene
   Expression in the Skin of Patients with Atopic Dermatitis and Psoriasis with Severe Itch. *J Invest Dermatol.* 2018;138(6):1311-1317. doi:10.1016/j.jid.2017.12.029
- Czarnowicki T, Krueger JG, Guttman-Yassky E. Skin Barrier and Immune Dysregulation in Atopic Dermatitis: An Evolving Story with Important Clinical Implications. *J Allergy Clin Immunol Pract*. 2014;2(4):371-379. doi:10.1016/J.JAIP.2014.03.006
- 9. Bin L, Leung DYM. Genetic and epigenetic studies of atopic dermatitis. *Allergy, Asthma Clin Immunol.* 2016;12(1):52. doi:10.1186/s13223-016-0158-5
- Margolis DJ, Apter AJ, Gupta J, et al. The persistence of atopic dermatitis and filaggrin (FLG) mutations in a US longitudinal cohort. *J Allergy Clin Immunol*. 2012;130(4):912-917. doi:10.1016/j.jaci.2012.07.008
- Smieszek SP, Welsh S, Xiao C, et al. Correlation of age-of-onset of Atopic Dermatitis
   with Filaggrin loss-of-function variant status. 2020:1-11. doi:10.1038/s41598-020-59627 7
- 299 12. Engebretsen KA, Bandier J, Kezic S, et al. Concentration of filaggrin monomers, its metabolites and corneocyte surface texture in individuals with a history of atopic dermatitis and controls. *J Eur Acad Dermatology Venereol*. 2018;32(5):796-804. doi:10.1111/jdv.14801
- Mischke D, Korge BP, Marenholz I, Volz A, Ziegler A. Genes Encoding Structural
   Proteins of Epidermal Cornification and S100 Calcium-Binding Proteins Form a Gene
   Complex (" Epidermal Differentiation Complex") on Human Chromosome
   Lq21. Vol 106.; 1996. doi:10.1111/1523-1747.ep12338501
- Kypriotou M, Huber M, Hohl D. The human epidermal differentiation complex: cornified envelope precursors, S100 proteins and the 'fused genes' family. *Exp Dermatol*.
   2012;21(9):643-649. doi:10.1111/j.1600-0625.2012.01472.x
- 310 15. Guttman-Yassky E, Suárez-Fariñas M, Chiricozzi A, et al. Broad defects in epidermal


- cornification in atopic dermatitis identified through genomic analysis. *J Allergy Clin Immunol*. 2009;124(6):1235-1244.e58. doi:10.1016/j.jaci.2009.09.031
- Jensen J-M, Fölster-Holst R, Baranowsky A, et al. Impaired Sphingomyelinase Activity and Epidermal Differentiation in Atopic Dermatitis. *J Invest Dermatol*. 2004;122(6):1423-1431. doi:10.1111/j.0022-202X.2004.22621.x
- 316 17. Sugiura H, Ebise H, Tazawa T, et al. Large-scale DNA microarray analysis of atopic skin lesions shows overexpression of an epidermal differentiation gene cluster in the alternative pathway and lack of protective gene expression in the cornified envelope. *Br J*
- 319 *Dermatol.* 2005;152(1):146-149. doi:10.1111/j.1365-2133.2005.06352.x
- Sandilands A, Terron-Kwiatkowski A, Hull PR, et al. Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema. *Nat Genet*. 2007;39(5):650-654. doi:10.1038/ng2020
- McAleer MA, Irvine AD. The multifunctional role of filaggrin in allergic skin disease. *J Allergy Clin Immunol*. 2013;131(2):280-291. doi:10.1016/j.jaci.2012.12.668
- 325 20. Brunner PM, Emerson RO, Tipton C, et al. Nonlesional atopic dermatitis skin shares similar T-cell clones with lesional tissues. *Allergy*. 2017;72(12):2017-2025. doi:10.1111/all.13223
- Ständer S, Yosipovitch G. Substance P and neurokinin 1 receptor are new targets for the treatment of chronic pruritus. *Br J Dermatol*. 2019;181(5):932-938.
   doi:10.1111/bjd.18025
- Azimi E, Reddy VB, Shade K-TC, et al. Dual action of neurokinin-1 antagonists on Masrelated GPCRs. *JCI Insight*. 2016;1(16):e89362. doi:10.1172/jci.insight.89362
- Teresiak-Mikołajczak E, Czarnecka-Operacz M, Jenerowicz D, Silny W. Neurogenic markers of the inflammatory process in atopic dermatitis: relation to the severity and pruritus. *Adv Dermatology Allergol*. 2013;5(5):286-292. doi:10.5114/pdia.2013.38357
- Schmitt J, Spuls P, Boers M, et al. Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. *Allergy*. 2012;67(9):1111-1117. doi:10.1111/j.1398-9995.2012.02874.x
- 339 25. Severity Scoring of Atopic Dermatitis: The SCORAD Index. *Dermatology*.
   340 1993;186(1):23-31. doi:10.1159/000247298
- Kleiner G, Marcuzzi A, Zanin V, Monasta L, Zauli G. Cytokine levels in the serum of healthy subjects. *Mediators Inflamm*. 2013;2013. doi:10.1155/2013/434010
- Hänel KH, Cornelissen C, Lüscher B, Baron JM. Cytokines and the skin barrier. *Int J Mol Sci.* 2013;14(4):6720-6745. doi:10.3390/ijms14046720
- 345 28. Karimkhani C, Silverberg JI, Dellavalle RP. Defining intrinsic vs. extrinsic atopic dermatitis. *Dermatol Online J.* 2015;21(6).
- Holm JG, Agner T, Clausen M-L, Thomsen SF. Determinants of disease severity among patients with atopic dermatitis: association with components of the atopic march. *Arch Dermatol Res.* 2019;311(3):173-182. doi:10.1007/s00403-019-01895-z
- Namkung J-H, Lee J-E, Kim E, et al. IL-5 and IL-5 receptor alpha polymorphisms are associated with atopic dermatitis in Koreans. *Allergy*. 2007;62(8):934-942. doi:10.1111/j.1398-9995.2007.01445.x

#### **Graphic Summary**





#### **Graphic Summary**

- A. Distinct endotypes and clinical presentation of AD as defined by IGA 1 and 2 (mild) and IGA 3 and 4 (moderate and severe)
- B. Distribution of clinical variables across endotypes as defined by IGA 1 and 2 (mild) and IGA 3 and 4 (moderate and severe)
- C. Significant differences in Eosinophil counts across endotypes as defined by IGA 1 and 2 (mild) and IGA 3 and 4 (moderate and severe)




**Figure 1** Hive plots of baseline clinical and lab values in association with severity as defined by IGA. Significant difference is displayed between IGA groups in A. SCORAD total score B. BSA C. Eosinophils (of particular interest are the cases > 0.5) D. IgE > 100 as marked by the red line. All significant results denoted by a \*/\*\*/\*\*\*.





#### **FLG LOF's**




**Figure 3.** Lollipop plots display the location and frequency of the identified variants in *Filaggrin*. We observe a significant enrichment of rare LOF variants in *FLG* detected in moderate and severe AD patients (IGA 3 and 4) as compared to mild AD (IGA 1 and 2).


## Figure4

Blood Cytokine Panel Ratio to reference range

medRxiv preprint doi: https://doi.org/10.1101/2020.04.16.20058677; this version posted April 20, 2020. The copyright holder for this prep (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.








Figure 4b. Scatter plots of cytokine levels across IGA categories

Table 1. Baseline demographic and clinical characteristics

medRxiv preprint doi: https://doi.org/10.1101/2020.04.16.20058677; this version posted April 20, 2020. The copyright holder for this preprint which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without paraliasion.

Age, mean (SD)	41.6 (15.3)
Male, n (%)	118 (34.6)
Ethnic origin, n (%)	
White	228 (66.9)
Black	83 (24.3)
Asian	19 (5.6)
Other	11 (3.2)
BMI (kg/m2)	28.2 (5.2)
Worst Itch- NRS	8.2 (1.3)
BSA	14.21 (17.2)
SCORAD	50.5 (14.5)
EASI	10.54 (10.4)
vIGA-AD, n (%)	
Almost Clear (1)	2 (0.6)
Mild (2)	77 (22.6)
Moderate (3)	218 (63.9)
Severe (4)	44 (12.9)
Eosinophil Count (10 <sup>9</sup> /L)	0.25 (0.2)
FLG LOF	51 (15.4)
IgE, n (% of >= 100 kU/L)	167 (49.0)

### SUPPLEMENTARY MATERIAL


medRxiv preprint doi: https://doi.org/10.1101/2020.04.16.20058677; this version posted April 20, 2020. The copyright holder for this prep (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

# S. Figure 1

Decision Tree


medRxiv preprint doi: https://doi.org/10.1101/2020.04.16.20058677; this version posted April 20, 2020. The copyright holder for this prep
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.



## S2. IL5RA rare variants in silico IL panel (described not a figure) medRxiv preprint dd: https://doi.org/10.1101/2020.04.16.20058677; this version posted pril 20, 2020. The copyright holder for this preprint was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


#### rs200005614



### S3 PCA of the WGS data

medRxiv preprint doi: https://doi.org/10.1101/2020.04.16.20058677; this version posted April 20, 2020. The copyright holder for this prep (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.


All rights reserved. No reuse allowed without permission.



## S4 IgE SCORAD and EOS

medRxiv preprint doi: https://doi.org/10.1101/2020.04.16.20058677; this version posted April 20, 2020. The copyright holder for this prep (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.



## S5 FLG S tables

medRxiv preprint doi: https://doi.org/10.1101/2020.04.16.20058677; this version posted April 20, 2020. The copyright holder for this prep (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.

VARIANTS IGA1+2 IGA3+4

	P value	OR	CI	Pvalue	OR	CI
501X	0.6584	1.936	(0.994 to 3.769)	0.0588	1.4	(0.3404 to 0.649)
2284FS	0.4593	1.497	(0.472 to 4.750)	0.0042	2.3	(1.393 to 3.963)
LOF ALL	0.9999	0.8993	(0.391 to 2.069)	<0.0001	2.3	(1.683 to 3.208)

#### Below is the MAF table

	501				
MAF	white	501	2284fs	LOF	rsSB_all
1and2	0.0212	0.0128	0.0192	0.0384	0.198
3and4	0.02	0.0177	0.0295	0.0885	0.216
GNOMAD	0.0163	0.009386	0.01314	0.0451	0.16